Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Open access
Kennedy, Nicholas A, Goodhand, James R, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Lin, Simeng, Chanchlani, Neil, Butterworth, Jeffrey, Cooney, Rachel, Croft, Nicholas M, Hart, Ailsa L, Irving, Peter M, Kok, Klaartje B, Lamb, Christopher A, Limdi, Jimmy K, Macdonald, Jonathan, McGovern, Dermot PB, Mehta, Shameer J, Murray, Charles D, Patel, Kamal V, Pollok, Richard CG, Raine, Timothy, Russell, Richard K, Selinger, Christian P, Smith, Philip J, Bowden, Jack, McDonald, Timothy J, Lees, Charlie W, Sebastian, Shaji, Powell, Nicholas, Ahmad, Tariq · 2021 · Gut

Abstract

Objective: Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections. Design: Antibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. 6935 patients were recruited from 92 UK hospitals between 22 September and 23 December 2020. Results: Rates of symptomatic and proven SARS-CoV-2 infection were similar between groups. Seroprevalence was lower in infliximab-treated than vedolizumab-treated patients (3.4% (161/4685) vs 6.0% (134/2250), p<0.0001). Multivariable logistic regression analyses confirmed that infliximab (vs vedolizumab; OR 0.66 (95% CI 0.51 to 0.87), p=0.0027) and immunomodulator use (OR 0.70 (95% CI 0.53 to 0.92), p=0.012) were independently associated with lower seropositivity. In patients with confirmed SARS-CoV-2 infection, seroconversion was observed in fewer infliximab-treated than vedolizumab-treated patients (48% (39/81) vs 83% (30/36), p=0.00044) and the magnitude of anti-SARS-CoV-2 reactivity was lower (median 0.8 cut-off index (0.2–5.6) vs 37.0 (15.2–76.1), p<0.0001). Conclusions: Infliximab is associated with attenuated serological responses to SARS-CoV-2 that were further blunted by immunomodulators used as concomitant therapy. Impaired serological responses to SARS-CoV-2 infection might have important implications for global public health policy and individual anti-TNF-treated patients. Serological testing and virus surveillance should be considered to detect suboptimal vaccine responses, persistent infection and viral evolution to inform public health policy. Trial registration number: ISRCTN45176516 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2021-324388

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 163

Metadata

Authors
Kennedy, N. A., Goodhand, J. R., Bewshea, C., Nice, R., Chee, D., Lin, S., Chanchlani, N., Butterworth, J., Cooney, R., Croft, N. M., Hart, A. L., Irving, P. M., Kok, K. B., Lamb, C. A., Limdi, J. K., Macdonald, J., McGovern, D. P., Mehta, S. J., Murray, C. D., Patel, K. V., Pollok, R. C., Raine, T., Russell, R. K., Selinger, C. P., Smith, P. J., Bowden, J., McDonald, T. J., Lees, C. W., Sebastian, S., Powell, N., & Ahmad, T.
Venue
Gut
Publisher
BMJ
Published
2021-03-22
Volume
70
Issue
5
Pages
865-875
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3137275528
Cited by
163
References
9
FWCI
18.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. https://app.cochat.ai/papers/10.1136/gutjnl-2021-324388
The paper
Kennedy, N. A., Goodhand, J. R., Bewshea, C., Nice, R., Chee, D., Lin, S., Chanchlani, N., Butterworth, J., Cooney, R., Croft, N. M., Hart, A. L., Irving, P. M., Kok, K. B., Lamb, C. A., Limdi, J. K., Macdonald, J., McGovern, D. P., Mehta, S. J., Murray, C. D., . . . Ahmad, T. (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. https://doi.org/10.1136/gutjnl-2021-324388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.